Literature DB >> 17413127

Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling.

Laimute Taraseviciene-Stewart1, Mark R Nicolls, Donatas Kraskauskas, Robertas Scerbavicius, Nana Burns, Carlyne Cool, Kathy Wood, Jane E Parr, Susan A Boackle, Norbert F Voelkel.   

Abstract

RATIONALE: Severe pulmonary arterial hypertension (SPH) is a frequently lethal condition characterized by pulmonary vascular remodeling and right heart strain or failure. SPH is also often associated with autoimmune and collagen vascular disorders.
OBJECTIVES: To study the effects of T cells on the development of experimental SPH.
METHODS: Athymic nude rats lacking T cells were treated with a single subcutaneous injection of vascular endothelial growth factor (VEGF) receptor blocker SU5416 (20 mg/kg) to induce pulmonary vascular endothelial cell apoptosis. Immunohistochemical analysis and IL-4 levels of the lung tissue were performed. Cell death and proliferation were assessed by Western blot and immunohistochemistry.
MEASUREMENTS AND MAIN RESULTS: In contrast to SU5416-treated euthymic rats that develop SPH only in combination with chronic hypoxia, athymic nude rats developed SPH and vascular remodeling (similar to clinical SPH) at normoxic conditions as demonstrated by measurements of pulmonary artery pressure and right ventricle hypertrophy. Pulmonary arterioles became occluded with proliferating endothelial cells and were surrounded by mast cells, B cells, and macrophages. IL-4, proliferating cell nuclear antigen, and collagen type I levels were markedly increased in SU5416-treated athymic rat lungs. Antibody deposition was noted along the vascular endothelium in rats with SPH. Finally, protection from SPH was conferred by immune challenge with spleen cells from euthymic nude rats.
CONCLUSIONS: These studies demonstrate the importance of a complete, intact immune system in protecting against pulmonary angioproliferation in this new model of SPH as well as the importance of intact VEGF receptor signaling for lung endothelial cell homeostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17413127      PMCID: PMC2176089          DOI: 10.1164/rccm.200608-1189OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  51 in total

1.  Soluble and cellular markers of immune activation in patients with systemic sclerosis.

Authors:  D Degiannis; J R Seibold; M Czarnecki; J Raskova; K Raska
Journal:  Clin Immunol Immunopathol       Date:  1990-08

Review 2.  Pulmonary hypertension in pulmonary parenchymal disease.

Authors:  D Heath
Journal:  Cardiovasc Clin       Date:  1972

3.  Lung mast cell hyperplasia and pulmonary histamine-forming capacity in hypoxic rats.

Authors:  J M Kay; J C Waymire; R F Grover
Journal:  Am J Physiol       Date:  1974-01

4.  Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus.

Authors:  F P Quismorio; O Sharma; M Koss; T Boylen; A W Edmiston; P J Thornton; D Tatter
Journal:  Semin Arthritis Rheum       Date:  1984-05       Impact factor: 5.532

Review 5.  Cellular and molecular pathobiology of pulmonary arterial hypertension.

Authors:  Marc Humbert; Nicholas W Morrell; Stephen L Archer; Kurt R Stenmark; Margaret R MacLean; Irene M Lang; Brian W Christman; E Kenneth Weir; Oliver Eickelberg; Norbert F Voelkel; Marlene Rabinovitch
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

6.  Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma.

Authors:  W P Follansbee; E I Curtiss; T A Medsger; V D Steen; B F Uretsky; G R Owens; G P Rodnan
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

7.  Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus.

Authors:  M-F Liu; C-R Wang; L-L Fung; C-R Wu
Journal:  Scand J Immunol       Date:  2004-02       Impact factor: 3.487

8.  Anti-endothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms.

Authors:  E Bodolay; I Csipo; I Gál; S Sipka; E Gyimesi; Z Szekanecz; G Szegedi
Journal:  Clin Exp Rheumatol       Date:  2004 Jul-Aug       Impact factor: 4.473

Review 9.  Primary heart disease in systemic sclerosis (scleroderma): advances in clinical and pathologic features, pathogenesis, and new therapeutic approaches.

Authors:  G R Botstein; E C LeRoy
Journal:  Am Heart J       Date:  1981-11       Impact factor: 4.749

10.  Lung mast cell density and distribution in chronically hypoxic animals.

Authors:  A Tucker; I F McMurtry; A F Alexander; J T Reeves; R F Grover
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1977-02
View more
  63 in total

1.  Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans.

Authors:  Harm J Bogaard; Shiro Mizuno; Christophe Guignabert; Aysar A Al Hussaini; Daniela Farkas; Gerrina Ruiter; Donatas Kraskauskas; Elie Fadel; Jeremy C Allegood; Marc Humbert; Anton Vonk Noordegraaf; Sarah Spiegel; Laszlo Farkas; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

Review 2.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 3.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

Review 4.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 5.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

6.  Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats.

Authors:  Daniela Farkas; Aysar A Alhussaini; Donatas Kraskauskas; Vita Kraskauskiene; Carlyne D Cool; Mark R Nicolls; Ramesh Natarajan; Laszlo Farkas
Journal:  Am J Respir Cell Mol Biol       Date:  2014-09       Impact factor: 6.914

7.  Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.

Authors:  Helen Christou; Ossama M Reslan; Virak Mam; Alain F Tanbe; Sally H Vitali; Marlin Touma; Elena Arons; S Alex Mitsialis; Stella Kourembanas; Raouf A Khalil
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

8.  Prolonged activation of IL-5-producing ILC2 causes pulmonary arterial hypertrophy.

Authors:  Masashi Ikutani; Koichi Tsuneyama; Makoto Kawaguchi; Junya Fukuoka; Fujimi Kudo; Susumu Nakae; Makoto Arita; Yoshinori Nagai; Satoshi Takaki; Kiyoshi Takatsu
Journal:  JCI Insight       Date:  2017-04-06

9.  Interleukin-6 overexpression induces pulmonary hypertension.

Authors:  M Kathryn Steiner; Olga L Syrkina; Narasaish Kolliputi; Eugene J Mark; Charles A Hales; Aaron B Waxman
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

10.  Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension.

Authors:  Rasa Tamosiuniene; Olga Manouvakhova; Paul Mesange; Toshie Saito; Jin Qian; Mrinmoy Sanyal; Yu-Chun Lin; Linh P Nguyen; Amir Luria; Allen B Tu; Joshua M Sante; Marlene Rabinovitch; Desmond J Fitzgerald; Brian B Graham; Aida Habtezion; Norbert F Voelkel; Laure Aurelian; Mark R Nicolls
Journal:  Circ Res       Date:  2018-03-15       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.